In a significant ruling, the U.S. District Court for the Northern District of Illinois has denied a motion to dismiss a lawsuit filed by Abbott Laboratories against its former employee Chad Amato and his new employer, Impulse Dynamics USA, Inc. The court's decision allows Abbott to pursue claims of misappropriation of trade secrets and breach of contract, which could have major implications for both parties.
The case, Abbott Laboratories and St. Jude Medical S.C. Inc. v. Chad Amato and Impulse Dynamics USA, Inc., was filed under docket number 1:26-cv-11561. Abbott, a leading manufacturer of medical devices, alleges that Amato misused confidential information after resigning from his position and starting work with Impulse Dynamics. This ruling is crucial as it addresses the protection of trade secrets in a competitive industry.
Background
Abbott Laboratories is a global healthcare company that produces medical devices, including those used for cardiac rhythm management (CRM). The CRM market is highly competitive, and Abbott invests heavily in developing relationships with healthcare providers and protecting its proprietary information. The company claims to have developed substantial confidential information, including trade secrets related to pricing, product launches, and physician training.
Chad Amato worked for Abbott from 2010 until his resignation on September 1, 2026. During his tenure, he rose to lead Abbott's West Coast CRM business, gaining access to sensitive information critical to the company's operations. Abbott and Amato had entered into an Employment Agreement in February 2018, which included non-compete clauses and confidentiality obligations.
Upon resigning, Amato immediately began working for Impulse Dynamics, a competitor in the CRM market. Abbott alleges that Amato forwarded confidential information to his personal email and accessed sensitive data shortly before his departure. Abbott filed its lawsuit on September 21, 2026, claiming breach of contract, tortious interference, and misappropriation of trade secrets.
The Ruling
The court, presided over by Judge Jorge L. Alonso, ruled against the defendants' motion to dismiss the case. The court found that the Employment Agreement's forum selection clause, which specified Illinois as the jurisdiction for disputes, was valid and enforceable. The court stated, "The parties agree to the exclusive jurisdiction of the state and federal courts in Illinois..." This ruling confirms that the case will proceed in Illinois, despite the defendants' arguments regarding California labor laws.
Additionally, the court addressed the defendants' claim of a first-to-file rule, which suggests that the first case filed in court should take precedence. The court determined that Abbott's lawsuit was a coercive action seeking broader relief compared to Amato's earlier declaratory judgment action in California, which sought to invalidate parts of the Employment Agreement. The court emphasized that it had the discretion to prioritize Abbott's case, stating, "For these reasons, the Court exercises its discretion and departs from the first-to-file rule."
Impact
This ruling is significant for Abbott Laboratories as it allows the company to pursue its claims against Amato and Impulse Dynamics. If Abbott can prove its allegations, it may recover damages and enforce its trade secret protections, which are vital for maintaining its competitive edge in the medical device market. The decision also reinforces the importance of confidentiality agreements and the legal enforceability of forum selection clauses in employment contracts.
The outcome of this case could set a precedent for similar disputes involving trade secrets and employee mobility in the healthcare industry. Companies may be more inclined to enforce their confidentiality agreements and take legal action against former employees who join competitors, particularly in industries where proprietary information is crucial for success.
What's Next
The case will move forward in the Northern District of Illinois, with a status hearing scheduled for October 8, 2026. Given the court's ruling, it is unlikely that the defendants will be able to appeal the decision at this stage. However, they may continue to contest the case's merits as it progresses through the legal system.